Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Agios Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.95% $29.74
Last updated: 8 aug 2022 - 0:36
TimeZone: America/New_York
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 630.29 mill |
| EPS: | -6.43 |
| P/E: | 0.000 |
| Earnings Date: | Nov 01, 2022 |
| SharesOutstanding: | 54.82 mill |
| Avg Daily Volume: | 0.731 mill |
| RATING 2022-08-05 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$32.68 (9.90%) $2.94 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 28.11 - 31.37 ( +/- 5.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-21 | Scadden David | Buy | 29 307 | Stock options (right to buy) |
| 2022-06-21 | Scadden David | Buy | 4 975 | Restricted stock unit |
| 2022-06-21 | Schenkein David P | Buy | 29 307 | Stock options (right to buy) |
| 2022-06-21 | Schenkein David P | Buy | 4 975 | Restricted stock unit |
| 2022-06-21 | Maraganore John | Buy | 29 307 | Stock options (right to buy) |
| INSIDER POWER |
|---|
| 72.30 |
| Last 100 transactions |
| Buy: 770 599 | Sell: 106 119 |
Live Trading Signals (every 1 min)
-10.00
Sell
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $29.74 (3.95% ) |
| Volume | 1.056 mill |
| Avg. Vol. | 0.731 mill |
| % of Avg. Vol | 144.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AGIO
101 Signals | Accuracy: 18.81% | Accuracy Buy: 28.00% | Accuracy Sell: 9.80%
Avg return buy: 0.44 % | Avg return sell: 0.36 %
$1 invested is now $1.23 or 22.86% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 15:44 | buy | $29.88 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 15:37 | sell | $29.84 | $29.88 @ Aug 5 - 15:44 | 0.13% |
| Aug 5 - 15:36 | buy | $29.87 | $29.84 @ Aug 5 - 15:37 | -0.10% |
| Aug 5 - 15:34 | sell | $29.85 | $29.87 @ Aug 5 - 15:36 | 0.07% |
| Aug 5 - 15:21 | buy | $29.91 | $29.85 @ Aug 5 - 15:34 | -0.18% |
| Aug 5 - 15:19 | sell | $29.81 | $29.91 @ Aug 5 - 15:21 | 0.32% |
| Aug 5 - 15:16 | buy | $29.90 | $29.81 @ Aug 5 - 15:19 | -0.28% |
| Aug 5 - 15:15 | sell | $29.82 | $29.90 @ Aug 5 - 15:16 | 0.27% |
| Aug 5 - 15:12 | buy | $29.84 | $29.82 @ Aug 5 - 15:15 | -0.08% |
| Aug 5 - 15:01 | sell | $29.83 | $29.84 @ Aug 5 - 15:12 | 0.05% |
AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Latest Press Releases
Latest News
